$CLDA News

Last published 15y ago

15y agoFRX CLDAForest Laboratories Completes Acquisition of Clinical Data, Inc.Business WireNEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) (“Forest”) today announced that it has successfully completed its acquisition of Clinical Data, Inc. (NASDAQ: CLDA) (“Clinical Data”) by means of what is known as a short-form merger under Delaware law.
15y agoCLDA FRXThe Law Offices of Vincent Wong Announce an Investigation into Possible Breaches of Fiduciary Duty by the Board of Clinical Data, Inc. in Connection with the Sale of the Company to Forest Laboratories, Inc. – CLDABusiness WireNEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong are investigating the Board of Directors of Clinical Data, Inc. (Nasdaq: CLDA) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Forest Laboratories, Inc. (NYSE: FRX). Under the terms of the transaction, Clinical Data shareholders will receive $30.00 per share in cash, w ...
15y agoCLDA FRXBrower Piven Announces an Investigation of the Acquisition of Clinical Data, Inc. by Forest Laboratories, Inc.Business WireSTEVENSON, Md.--(BUSINESS WIRE)--The law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Clinical Data, Inc. (“Clinical Data”) (NASDAQ:CLDA) and other violations of state law by the Board of Directors of Clinical Data relating to the proposed acquisition of the company by Forest Laboratories, Inc. ...
15y agoCLDAGoldman Scarlato & Karon, P.C. Announces Investigation of Clinical Data, Inc.Business WireCONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Goldman Scarlato & Karon, P.C. (“GSK”) is investigating potential legal claims against the Board of Directors of Clinical Data, Inc. (“Clinical Data”) (NASDAQ: CLDA) relating to the proposed buyout of Clinical Data by Forest Laboratories, Inc. The definitive acquisition agreement, announced on February 22, 2011, involves an all-cash, going-private transaction va ...
15y agoCLDABull & Lifshitz, LLP Announces Investigation of the Acquisition of Clinical Data, Inc.Business WireNEW YORK--(BUSINESS WIRE)--Bull & Lifshitz, LLP announces an investigation into possible breaches of fiduciary duty in connection with the proposed acquisition of Clinical Data, Inc. (NASDAQ: CLDA) (referred to as "Clinical Data" or the “Company”) by Forest Laboratories, Inc. (“Forest”) in a cash transaction valued at approximately $1.2 billion.
15y agoCLDARyan & Maniskas, LLP Announces Investigation of Clinical Data, Inc.Business WireWAYNE, Pa.--(BUSINESS WIRE)--Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/clda) is investigating potential claims against the board of directors of Clinical Data, Inc. ("Clinical Data" or the "Company") (NASDAQ: CLDA) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s efforts to sell Clinical Data to Forest Laboratories, Inc. in a transaction with ...
15y agoCLDA FRXThe Law Office of Abe Shainberg Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Clinical Data, Inc. in Connection with the Sale of the Company to Forest Laboratories, Inc. – CLDABusiness WireNEW YORK--(BUSINESS WIRE)--The Law Office of Abe Shainberg is investigating the Board of Directors of Clinical Data, Inc. (Nasdaq: CLDA) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Forest Laboratories, Inc. (NYSE: FRX). Under the terms of the transaction, Clinical Data shareholders will receive $30.00 per share in cash, wi ...
15y agoCLDA FRXRobbins Umeda LLP Is Investigating Clinical Data, Inc. Acquisition for ShareholdersBusiness WireSAN DIEGO--(BUSINESS WIRE)--Robbins Umeda LLP, a shareholder rights litigation firm, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by members of the board of directors of Clinical Data, Inc. (NASDAQ: CLDA) in connection with their efforts to sell the company to Forest Laboratories, Inc. (NYSE: FRX). Under the proposed agreement, Forest La ...
15y agoCLDAFinkelstein Thompson LLP Announces Investigation of Clinical Data, Inc.Business WireWASHINGTON--(BUSINESS WIRE)--Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Clinical Data, Inc. (“Clinical Data” or the “Company”) (Nasdaq:CLDA) concerning the proposed acquisition of the Company by Forest Laboratories, Inc (“Forest”). Under the terms of the offer, Clinical Data shareholders will receive $30.00 in cash per share owned and contingent conside ...
15y agoCLDAKendall Law Group Investigates Clinical Data, Inc. for ShareholdersBusiness WireDALLAS--(BUSINESS WIRE)--Kendall Law Group, led by former federal judge Joe Kendall, is investigating Clinical Data, Inc. (NASDAQ: CLDA) for shareholders in connection with the proposed acquisition by Forest Laboratories, Inc. The national securities firm’s investigation seeks to determine whether Clinical Data and its Board breached their fiduciary duties by entering into the agreement without pr ...
15y agoCLDA FRXRigrodsky & Long, P.A. Investigates Buyout of Clinical Data, Inc. - CLDABusiness WireWILMINGTON, Del.--(BUSINESS WIRE)--Rigrodsky & Long, P.A. announces that it is investigating potential claims against the board of directors of Clinical Data, Inc. (“Clinical Data” or the “Company”) (Nasdaq: CLDA) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s entry into an agreement to be acquired by Forest Laboratories, Inc. (“Forest Labs”) (N ...
15y agoCLDAHarwood Feffer LLP Announces Investigation of Clinical Data, Inc.Business WireNEW YORK--(BUSINESS WIRE)--Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Clinical Data, Inc. (NASDAQ - CLDA) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell CLDA to Forest Laboratories Inc. (NYSE – FRX) in a transaction valued at approximately $1 billion.
15y agoFRX CLDAForest Laboratories to Acquire Clinical Data, Inc.Business WireNEW YORK & NEWTON, Mass.--(BUSINESS WIRE)--Forest Laboratories, Inc. (Forest) (NYSE: FRX) and Clinical Data, Inc. (Clinical Data) (NASDAQ: CLDA) today announced that they have entered into a definitive merger agreement pursuant to which Forest will acquire Clinical Data, a specialty pharmaceutical company focused on the development of first-in-class and best-in-category therapeutics, for $30.00 pe ...
15y agoCLDAClinical Data, Inc. Reports Third Quarter Fiscal Year 2011 Operational and Financial ResultsBusiness WireNEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ: CLDA) today announced operational and financial results for the third fiscal quarter ended December 31, 2010. The Company received approval from the U.S. Food and Drug Administration (FDA) of Viibryd™ for the treatment of adults with major depressive disorder (MDD) on January 21, 2011. In addition, Phase III development of Stedivaze, the ...
15y agoCLDAClinical Data, Inc. to Present at the BIO CEO & Investor ConferenceBusiness WireNEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ: CLDA) today announced that Drew Fromkin, President and Chief Executive Officer, will be presenting a corporate overview at the 13th Annual BIO CEO & Investor Conference. Clinical Data's presentation will take place at 9:00 a.m. EST on Tuesday, February 15, 2011 at The Waldorf-Astoria in New York, NY.
15y agoCLDAClinical Data, Inc. Announces FDA Approval of Viibryd™ (vilazodone HCl) for Major Depressive DisorderBusiness WireNEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ: CLDA), today announced that the U.S. Food and Drug Administration (FDA) has approved vilazodone HCl tablets, to be marketed under the brand name Viibryd™, for the treatment of adults with major depressive disorder (MDD).1 Viibryd is a new molecular entity and the first and only selective serotonin reuptake inhibitor and 5HT1A receptor pa ...